Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2010 |
| End Date: | April 2012 |
A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer
Tesetaxel is an orally administered chemotherapy agent of the taxane class. The dose of a
chemotherapy agent is typically based on the patient's body surface area. Flat dosing is
desirable in the clinical setting. Pharmacokinetic and safety data from completed Phase II
studies suggest that administration of tesetaxel at a flat dose is appropriate. This study
is being undertaken to evaluate the efficacy and safety of tesetaxel administered as
second-line therapy at a flat dose to patients with advanced gastric cancer.
We found this trial at
2
sites
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
Click here to add this to my saved trials